Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(14):1118-1120; doi:10.1093/jnci/92.14.1118
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Gottlieb, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gottlieb, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 14, 1118-1120, July 19, 2000
© 2000 Oxford University Press

NEWS

Nonhormonal Agents Show Promise Against Hot Flashes

Nicole Gottlieb

Breast cancer survivors who experience debilitating hot flashes now have a new remedy: venlafaxine (Effexor), a drug used as an antidepressant. Charles Loprinzi, M.D., of the Mayo Clinic Cancer Center in Rochester, Minn., presented his results in May at the annual meeting of the American Society of Clinical Oncology, concluding that venlafaxine at 75 mg per day reduces hot flashes in breast cancer patients by approximately 60% from baseline. This 60% reduction is in a hot flash "score" that accounts for both the frequency and severity of hot flashes.



View larger version (131K):
[in this window]
[in a new window]
  		Dr. Charles Loprinzi

 
The 75 mg dose gave the best ratio of benefits . . . [Full Text of this Article]

Blood Pressure Medications

SSRIs ‘Most Promising’


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?